[HTML][HTML] PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma

PT Nghiem, S Bhatia, EJ Lipson… - … England Journal of …, 2016 - Mass Medical Soc
Background Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma …

[HTML][HTML] Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN …

SP D'Angelo, S Bhatia, AS Brohl, O Hamid… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …

Tuberculosis following PD-1 blockade for cancer immunotherapy

DL Barber, S Sakai, RR Kudchadkar, SP Fling… - Science translational …, 2019 - science.org
Because of the well-established therapeutic benefit of boosting antitumor responses through
blockade of the T cell inhibitory receptor PD-1, it has been proposed that PD-1 blockade …

[HTML][HTML] Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

NA Giraldo, P Nguyen, EL Engle, GJ Kaunitz… - … for immunotherapy of …, 2018 - Springer
Background We recently reported a 56% objective response rate in patients with advanced
Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting …

Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia

RD Cassaday, KLA Garcia, JR Fromm… - Blood …, 2020 - ashpublications.org
The presence of measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL)
confers a poor prognosis. CD19-targeted immunotherapy is effective against MRD but is …

[PDF][PDF] New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy

E Greene, G Finak, LA D'Amico, N Bhardwaj… - Patterns, 2021 - cell.com
We introduce a new method for single-cell cytometry studies, FAUST, which performs
unbiased cell population discovery and annotation. FAUST processes experimental data on …

CD200 expression in neuroendocrine neoplasms

JE Love, K Thompson, MR Kilgore… - American journal of …, 2017 - academic.oup.com
Objectives CD200 expression has been well studied in hematopoietic malignancies;
however, CD200 expression has not been well-characterized in neuroendocrine …

T antigen-specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma

UK Hansen, CD Church, AMC Simões… - The Journal of …, 2024 - Am Soc Clin Investig
Merkel cell carcinoma (MCC) is a highly immunogenic skin cancer primarily induced by
Merkel Cell Polyomavirus, driven by the expression of the oncogenic T antigens (T-Ags) …

[HTML][HTML] Quality is king: fundamental insights into tumor antigenicity from virus-associated Merkel cell carcinoma

MC Lahman, KG Paulson, PT Nghiem… - Journal of Investigative …, 2021 - Elsevier
Merkel cell carcinoma (MCC) is a rare skin malignancy that is a paradigm cancer for solid
tumor immunotherapy. MCCs associated with Merkel cell polyomavirus (virus-positive MCC …

Effect of patient immune status on the efficacy of radiation therapy and recurrence-free survival among 805 patients with Merkel cell carcinoma

YD Tseng, MH Nguyen, K Baker, M Cook… - International Journal of …, 2018 - Elsevier
Purpose Patients with Merkel cell carcinoma (MCC) with chronic immunosuppression (IS)
have worse outcomes, but the mechanisms are not well understood. We hypothesized that …